LIXIL-FOUNDATION
The LIXIL Foundation (located in Koto-ku, Tokyo; Chairman: Yoko Ushioda), which facilitates surveys and research related to the housing and building materials industries as well as supporting the development of human resources, is pleased to announce today that the next-generation sustainable housing “INFINITE FIELD” designed by The Royal Danish Academy of Fine Arts (Denmark) has been completed on a site of Memu Meadows in Taiki-cho Hokkaido, environmental technology research facilities managed by the foundation.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161027007034/en/
INFINITE FIELD is the top prize winner in the 6th LIXIL International Student Architectural Competition sponsored by the LIXIL Foundation, aimed to seek and review next-generation sustainable housing technology and communicate that technology to the global community. The project was designed based on the theme: “Comfort and Lightness.” For the first time in its history, this year’s competition called for proposals for a light shelter that can be easily assembled and moved.
INFINITE FIELD is a structure that features a 360-degree timber platform and the design enveloped by soft, permeable membranes. From this elevated platform, which is aligned with an average snow depth in this region, users are able to enjoy the view of snowfield spreading infinitely during the winter months while the platform transforms into a place to cool off in the summer heat. It is designed to allow people to feel changes of the seasons in Taiki-cho.
The varied textile membranes invite nature in and allow the architecture in itself to move. The fabric is layered to create the space; these textiles are chosen with consideration of various environmental properties to ensure a comfortable thermal environment. Dwellers can operate these layered membranes on their own, adding or removing them to adjust their relationships with the environment while they serve as an expanded threshold.
With the completion of INFINITE FIELD, Memu Meadows is now a home to six structures designed by students. The effects of these “next-generation sustainable houses” will continue to be verified.
|
Accompanying Material |
||||||||
|
-- INFINITE FIELD designed by The Danish Royal Academy of Fine Arts (Denmark) |
||||||||
|
Supervisor: |
Anders Brix, Professor | |||||||
|
Students: |
Kazumasa Takada/Bas Spaanderman | |||||||
| Scarlett Emma Hessian/Jesse Thomas | ||||||||
| Benjamin Hock Yuu Tan/Konstantinos Fetsis | ||||||||
|
Design Supervisor: Kengo Kuma & Associates |
Structural Engineer: Oak Structural Design |
|
|
General Contractor: Takahashi Construction Company |
Building Area: 21.3m2 |
|
|
Construction Cost: Approx. 15 million yen |
||
|
Construction Period: August 2016 - October 2016 |
||
[Features]
-
Seasonal Transformation
INFINITE FIELD was imagined as a permeable experience, one where users are able to dictate their conditions, while engaging with the natural environment surrounding them. During the winter months it is from this elevated vantage point that users are aligned with an infinite sea of snow, and are treated to overlook the landscape from the warmth of the nest. In the summer heat the platform transforms into a place for rest and quiet reflection, looking out to a field of wild grasses, trees and bright blue skies. This 360-degree timber base is a contemplative oasis providing panoramic views of the natural surrounding. -
Spatial Tactility
INFINITE FIELD is an architecture of change and graduation, allowing users to experience and enjoy the shifting environment in comfort, while simultaneously enhancing our human connection with nature. A set of soft, permeable membranes made of varied textiles invites nature in and allows the design to move and breathe with the seasons. As you transition across the platform users can operate the membranes, moving them to add or remove barriers between the environment and themselves. These layers are an expanded threshold, an envelope inviting nature in while allowing a tactile interaction with the architecture. -
Material
Dwelling
The fabric architecture imparts a whole new perspective to familiar scenes. Silk fabric blades hang from the draped inner membrane disrupting heat and air flow. Users are able to visually perceive the gentle winds and air that flow through the dwelling as these fabric blades gently sway and flutter in the breeze. The project’s textiles are chosen with consideration of the various environmental properties, while their layered design provides adaptable thermal zones for user’s personal comfort.
-- Overview of Facility
Name:
Memu Meadows
Location:
158-1 Memu, Taiki-cho, Hiro-gun, Obihiro, Hokkaido
Owner:
LIXIL Foundation 2-1-1 Ojima, Koto-ku, Tokyo, 136-8535
Site
area:
App. 184,000 square meters
Main facilities:
Experimental
house “Même”, “Mock-up of Multiple floor Bamboo House”, “A recipe to
live”, “BARN HOUSE”, “HORIZON HOUSE”, “NEST WE GROW”, “INVERTED HOUSE”,
Multipurpose Facility, Conference Pavilion, Residence 1L and 1R
(accommodation for researchers), two log houses (accommodation for
researchers), fitness center, restaurant, Administration Wing, etc.
Official
website:
http://www.lixiljsfound.com/
View source version on businesswire.com: http://www.businesswire.com/news/home/20161027007034/en/
Contact:
LIXIL Foundation
Kenji Iida, +81-3-5626-1008
2-1-1, Oshima,
Koto-ku, Tokyo 136-8535
Fax: +81-3-5626-1033
LIXIL Foundation
website: http://www.lixiljsfound.com/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dompé Doses First Patients in Europe and US in Phase 3 Studyof Isocyclosporin for Atopic Keratoconjunctivitis16.12.2025 13:00:00 CET | Press release
Atopic keratoconjunctivitis(AKC) is a chronic inflammatory disease of the eye that is frequently associated with atopic conditions, and limited disease awareness often leads to delayed or missed diagnosis. Isocyclosporin is a novel, dual inhibitor oftwo critical immunepathways in ocular inflammation like AKC. Dompé, a leading biopharmaceutical company with operations in Italy and the U.S., announced the first patients have been enrolled in a Phase 3 study of Isocyclosporin for the treatment of atopic keratoconjunctivitis (AKC). Isocyclosporin is a dual inhibitor of transient receptor potential (TRP) cation channel, mucolipin subfamily, member 2 (TRPML2) and calcineurin, key regulators of immune and inflammatory response in chronic inflammatory eye diseases. The Phase 3 trial is a multicenter, randomized, double-masked study comparing isocyclosporin against vehicle control in improving ocular signs and symptoms after six weeks of treatment. “This milestone underscores Dompé’s commitment
Visa Launches Stablecoin Settlement in the United States, Marking a Breakthrough for Stablecoin Integration16.12.2025 13:00:00 CET | Press release
With more than $3.5B in annualized stablecoin settlement volume1, Visa brings USDC settlement to U.S. institutions. Visa Inc. (V) today announced the launch of USDC settlement in the United States, marking a major milestone in the company’s stablecoin settlement pilot program and strategy to modernize its settlement layer underpinning global commerce. For the first time, U.S. issuer and acquirer partners can settle with Visa in Circle’s USDC, a fully reserved, dollar-denominated stablecoin. With USDC settlement, issuers can benefit from faster funds movement over blockchains, seven‑day availability and enhanced operational resilience across weekends and holidays - without any change to the consumer card experience. Initial banking participants include Cross River Bank and Lead Bank, which have started settling with Visa in USDC over the Solana blockchain. Broader availability in the U.S. is planned through 2026. Additionally, Visa is a design partner for Arc, a new Layer 1 blockchain d
Volante Technologies Customers Successfully Navigate Critical Regulatory Deadlines for EU SEPA Instant and Global SWIFT Cross-Border Payments16.12.2025 10:00:00 CET | Press release
PaaS leader ensures seamless migrations and uninterrupted payment operations Volante Technologies, the global leader in Payments as a Service (PaaS), today announced it has successfully upgraded its clients to meet the latest SEPA Instant Payments Regulation (IPR) and SWIFT SRG 2025 mandate, which came into effect October 9th and November 22nd, 2025, respectively. This announcement follows the major FedISO upgrade in July, which shifted trillions of dollars in payments to the new ISO 20022 messaging format. SEPA IPR is a significant European milestone, requiring payments to be made within 10 seconds and at any time of day, throughout the year. Adoption was mandatory and Eurozone banks were compelled to meet strict deadlines, with January 9th, 2025 the deadline for receiving incoming instant payments and October 9th the deadline for sending outgoing instant payments. The latest deadline impacted more than 700 banks across Europe, with non-compliance penalties reaching at least 10% of an
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release
RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
